Shayan Mohammadmoradi/LinkedIn
Nov 7, 2026, 08:28
Shayan Mohammadmoradi: Targeting Inflammation in Atherosclerosis
Shayan Mohammadmoradi, Vascular Biology and Platelet Function Scientist at University of Kentucky, CEO at Moradi Enterprise, shared a post on LinkedIn:
“Strong opener at Scientific Sessions 26 on targeting inflammation in atherosclerosis: efferocytosis, resolution, tRNA-derived small RNAs, macrophage genomics, and Dr. Paul Ridker on where anti-inflammatory therapy goes next.
Thanks Yabing Chen and Katey Rayner for moderating!”
Other posts featuring Shayan Mohammadmoradi on Hemostasis Today.
-
Nov 7, 2026, 15:21Shamee Shastry: Improving the Reliability and Reproducibility of the Monocyte Monolayer Assay
-
Nov 7, 2026, 14:39AI-Assisted Donor Screening and Transfusion Decision Support: A Prospective Multicentre Evaluation
-
Nov 7, 2026, 14:26Qiong Tang: Changing Perspectives on Iron Deficiency and Supplementation
-
Nov 7, 2026, 14:21Nathan Connell: Bringing VWD Education Across Borders to Improve Patient Care
-
Nov 7, 2026, 14:02David McIntosh: Thalassaemia Care Needs More Than Breakthrough Therapies
-
Nov 7, 2026, 14:00Farzin Beygui: SOLOTAVI Tests Aspirin Discontinuation After TAVI
-
Nov 7, 2026, 13:50Edward Lee Carter: Is Aspirin Monotherapy Sufficient After Watchman Implantation?
-
Nov 7, 2026, 13:40Leticia Leal: Preventing Blood Clots During Long Flights
-
Nov 7, 2026, 12:06Kinza Raza: Giving Back Through Thalassaemia Awareness – A Journey Back to School